Revision of Applications for Manufacturing and Procurement Quotas
Key claim: The DEA proposes to revise manufacturing and procurement quota regulations for Schedule I/II controlled substances and List I chemicals to improve supply chain visibility, prevent drug shortages, and clarify domestic versus export subcategories.
Abstract
(Proposed Rule · Justice Department, Drug Enforcement Administration) The Drug Enforcement Administration (DEA) proposes to revise existing regulations relating to the management of quotas for schedule I and II controlled substances and the list I chemicals, ephedrine, pseudoephedrine, and phenylpropanolamine, to be utilized by DEA- registered manufacturers. This rule is being proposed to: restructure DEA’s manufacturing and procurement quota regulations for more clarity and consistency; clarify which use-specific subcategories for quotas should be used for controlled substances that will be sold domestically and controlled substances that will be exported; and revise the applications for individual manufacturing and procurement quota. The changes are necessary to increase visibility into the controlled substance supply chain by providing DEA with more detailed information allowing the agency to react more precisely in preventing drug shortages; and to ensure that enough of the schedule I and II controlled substances and three list I chemicals can be manufactured to meet estimated scientific, medical, lawful export, and inventory needs. This rule also contains revisions to use gender neutral language and other non-substantive revisions.
Why this matters
DEA manufacturing and procurement quotas set the ceiling on how much of each Schedule I/II substance (including ADHD stimulants and opioid analgesics) can be produced or procured domestically each year, so quota application rules directly shape whether patients experience shortages. Restructuring domestic vs. export subcategories and improving supply chain visibility could give DEA earlier signals of impending shortfalls and change how manufacturers justify quota requests. The proposal is a procedural revision — not a change to schedules or quantities themselves — but it affects the administrative pathway that governs controlled substance supply.